Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies

Page 4 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.

• Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CMLCompletedNCT00462943Phase 2Results posted
• Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic PhaseTerminatedNCT00451035Phase 2Results posted
• Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other DiseasesCompletedNCT00450450Phase 3Results posted
• Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast PhaseTerminatedNCT00449761Phase 2Results posted
• Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic MalignancyCompletedNCT00433745Phase 2Results posted
• Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00428077Phase 2Results posted
• TALL-104 and Gleevec in Chronic Myelogenous Leukemia PatientsTerminatedNCT00415909Phase 2Results posted
• Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)CompletedNCT00412360Phase 3Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)CompletedNCT00406393Phase 3Results posted
• Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
• Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated DonorTerminatedNCT00393380Phase 2Results posted
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
• Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsCompletedNCT00378534Phase 2Results posted
• Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene MutationCompletedNCT00375219Phase 2Results posted
• T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsCompletedNCT00368355Phase 2Results posted
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyTerminatedNCT00362466Phase 3Results posted
• An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous LeukemiaTerminatedNCT00346632Phase 1Results posted
• Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDSCompletedNCT00334074Phase 2Results posted
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaCompletedNCT00333840Phase 3Results posted
• Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to ImatinibTerminatedNCT00320190Phase 2Results posted
• Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantCompletedNCT00309907Phase 2Results posted
• Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
• Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual DiseaseCompletedNCT00267085Phase 2Results posted
• Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive LeukemiasCompletedNCT00261846Phase 2Results posted
• Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00254423Phase 2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular ResponseTerminatedNCT00210119Phase 2Results posted
• Haploid Allogeneic Transplant Using the CliniMACS SystemTerminatedNCT00185679Phase 2Results posted
• Stem Cell Transplant for Hematological MalignancyTerminatedNCT00176930Not applicableResults posted
• An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
• An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 2Results posted
• An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast CrisisCompletedNCT00171158Phase 2Results posted
• Post Transplant Donor Lymphocyte InfusionTerminatedNCT00167180Phase 2Results posted
• HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic MalignanciesCompletedNCT00145626Phase 2Results posted
• Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00129740Phase 2Results posted
• Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)TerminatedNCT00124748Phase 3Results posted
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CMLCompletedNCT00123474Phase 3Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)TerminatedNCT00114959Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
• Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCompletedNCT00103844Phase 2Results posted
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateCompletedNCT00101816Phase 2Results posted
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to ImatinibCompletedNCT00101660Phase 2Results posted
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid LeukemiaCompletedNCT00101647Phase 2Results posted
• Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantCompletedNCT00096161Phase 2Results posted
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
• Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3Results posted
• Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT00070499Phase 2Results posted
• Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell TransplantCompletedNCT00068718Phase 1/2Results posted
• Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
• Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
• Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CTerminatedNCT00038649Phase 2Results posted
• Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibCompletedNCT00036738Phase 2Results posted
• Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00022490Phase 2Results posted
• Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00015847Phase 2Results posted
• Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
• A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In GreeceActive, not recruitingNCT07814170Not applicable
• Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsActive, not recruitingNCT07789574Phase 2
• Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of TreatmentCompletedNCT07188428
• Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaActive, not recruitingNCT07166419Phase 1
• A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia PatientsCompletedNCT07151820
• A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in JapanCompletedNCT07150793
• Ropeginterferon for Treatment Free RemissionCompletedNCT07105319Phase 4
• Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination TherapyActive, not recruitingNCT07022743Phase 2
• TGRX-678 Pharmacokinetic Mass BalanceCompletedNCT06986772Phase 1
• Genomics Study in CML Patients With Ponatinib TreatmentCompletedNCT06945146
• TGRX-678 Phase I Oral Pharmacokinetic StudyCompletedNCT06697899Phase 1
• Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of TherapyCompletedNCT06692803
• ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisSuspendedNCT06680661Phase 2
• Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With AsciminibCompletedNCT06516029
• Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationCompletedNCT06427811Phase 4
• The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid LeukaemiaActive, not recruitingNCT06233890
• Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)CompletedNCT06211153
• Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims DatabaseCompletedNCT06148493
• Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in FranceActive, not recruitingNCT06092879
• Comorbidity Burden and Use of Concomitant Medications at CML DiagnosisCompletedNCT06042660
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
• Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
• Real-World Disease Management and Outcomes in Chronic Myeloid LeukaemiaCompletedNCT05893836
• Cord Blood Transplant in Adults With Blood CancersActive, not recruitingNCT05884333Phase 2
• Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)Active, not recruitingNCT05768711Phase 2
• Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune SystemActive, not recruitingNCT05753384Phase 3
• A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid LeukemiaCompletedNCT05743465
• Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent LineCompletedNCT05734053
• Venetoclax After TKI to Target Persisting Stem Cells in CMLCompletedNCT05701215Phase 2
• Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation BosutinibCompletedNCT05682924
• A Bioequivalence Study of Dasatinib TabletCompletedNCT05640804Phase 1
• Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous LeukemiaStatus unknownNCT05638763Phase 2
• French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML PatientsCompletedNCT05619978
• Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I MutationCompletedNCT05611216
• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesActive, not recruitingNCT05589896Phase 1/2
• "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"Status unknownNCT05543161

← Leukemia, Myelogenous, Chronic, BCR-ABL Positive overview